Modified Starch Liposome Encapsulation for Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional encapsulating agents used to transform biologically active agents into dry powders often compromise bioavailability, particularly for water-insoluble active agents like coenzyme Q10, requiring high doses to achieve effective levels due to limited oral bioavailability.
Innovation Solution
A modified starch, prepared by enzymatic hydrolysis of a starch derivative containing hydrophobic and hydrophilic groups, is used to encapsulate active agents in liposomes, resulting in a dry powder with enhanced bioavailability, stability, and high load levels, while minimizing surface oil exposure and oxidation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional encapsulating agents (gum arabic, dextrins, starches, gelatin, etc.) are used to transform active agents into dry powder, then the active agent can be delivered in solid dosage form, but the bioavailability of the active agent is substantially reduced
Solution Approach 1:
The patent uses a composite encapsulating system combining modified starch (with hydrophobic groups) and liposomes. The modified starch provides structural stability for solid dosage form, while the liposome component maintains bioavailability by protecting the active agent during digestion. This composite approach resolves the contradiction between solid form stability and bioavailability.
Solution Approach 2:
The patent modifies the chemical structure of starch by introducing hydrophobic groups (such as octenyl succinic groups) through reaction with anhydrides. This parameter change in the encapsulating agent's chemistry allows it to better interact with lipophilic active agents and maintain their bioavailability in dry powder form, while still providing the desired solid dosage characteristics.
2Stability of the object's composition
If conventional encapsulating agents are used to create dry powder, then the active agent is protected in solid form, but excessive dosing is required to achieve effective levels due to limited oral bioavailability
Solution Approach 1:
The liposome-modified starch composite provides enhanced protection and bioavailability compared to conventional single-material encapsulants. The liposome layer protects the active agent from degradation and facilitates absorption, reducing the quantity needed to achieve therapeutic effects while maintaining solid form stability.
Solution Approach 2:
The chemical modification of starch with hydrophobic groups changes the encapsulation properties, improving the interaction with lipophilic active agents and enhancing their release and absorption characteristics. This reduces the dosing amount required to achieve effective plasma levels.
3Adaptability or versatility
If starch is enzymatically hydrolyzed after derivatization with hydrophobic groups, then the modified starch provides both hydrophobic and hydrophilic properties for encapsulation, but the processing complexity increases
Solution Approach 1:
The starch is first derivatized with hydrophobic groups before enzymatic hydrolysis. This preliminary modification ensures that the hydrophobic groups are properly incorporated into the starch structure, and the subsequent hydrolysis creates the desired balance of hydrophobic and hydrophilic properties without requiring additional modification steps later in the process.
Solution Approach 2:
The enzymatic hydrolysis selectively modifies specific regions of the starch molecule, creating a gradient of hydrophobicity from the core to the surface. This local quality variation allows the encapsulating agent to simultaneously provide hydrophobic interaction for lipophilic agents and hydrophilic interaction for aqueous environments, enhancing versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified starch encapsulation method maintains high bioavailability of active agents, reduces the need for excessive dosing, and provides excellent oxidation resistance, ensuring effective delivery and prolonged shelf life of the encapsulated product.
Implementation Method 1
These compositions are prepared by emulsifying the active agent using liposome technology
Implementation Method 2
The modified starch is prepared by enzymatic hydrolysis of starch after the preparation of a starch derivative containing a hydrophobic group or both a hydrophobic and a hydrophilic group
Implementation Method 3
The composition has good load levels and stability... excellent oxidation resistance
Data Source
AI summary
The present invention is directed to a dry composition which allows delivery of active agents with good bioavailability. These compositions are prepared by emulsifying the active agent using liposome technology known in the art and then encapsulating with a modified starch. The modified starch is prepared by enzymatic hydrolysis of starch after the preparation of a starch derivative containing a hydrophobic group or both a hydrophobic and a hydrophilic group. The resultant composition is a dry powder with excellent bioavailability. Further, the composition has good load levels and stability.